Genmab — August 2023
-
Topline Results for Phase 3 innovaTV 301 Clinical Trial Anticipated As Early As YE23: The Company expects to report topline results of the phase 3 innovaTV 301 clinical trial evaluating TIVDAK monotherapy versus investigator choice chemotherapy for patients with second- or third-line recurrent or metastatic cervical cancer.
-
-
Hvad skal der efterhånden til for at få Genmab til at stige? Alle positive nyheder, som opjusteringer, bliver affærdiget af analytikerne som "indpriset i den nuværende kurs". Hvis nu man kunne lave det tankeeksperiment at J.v.W satte Warrentsprogrammet på "pause", og i stedet brugte noget af overskuddet på udbytte de almindeligt dødelige - nemlig aktionærerne, så ville det være svært at forklare, at det var indpriset!
-
NBI -0.65%.
-
In summary, our results assert the potential of epcoritamab as a novel treatment option for patients with CLL and support clinical investigations of epcoritamab in combination with BTKis or venetoclax and as salvage therapy in patients with progressing disease while receiving BTKi therapy.
-
-
Passer fint med at venetoclax er med i Epcore cll https://classic.clinicaltrials.gov/ct2/show/NCT04623541?term=Epcore+cll+1&draw=2&rank=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind